Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma

Michael Brada; Sally Stenning; Rhian Gabe; Lindsay C Thompson; David Levy; Roy Rampling; Sara Erridge; Frank Saran; Rao Gattamaneni; Kirsten Hopkins; Sarah Beall; V Peter Collins; Siow-Ming Lee

doi:10.1200/JCO.2009.27.1932

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma

Michael Brada, Sally Stenning, Rhian Gabe, Lindsay C Thompson, David Levy, Roy Rampling, Sara Erridge, Frank Saran, Rao Gattamaneni, Kirsten Hopkins, Sarah Beall, V Peter Collins, Siow-Ming Lee

The Hull York Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG.

Original language	English
Pages (from-to)	4601-1408
Number of pages	8
Journal	Journal of Clinical Oncology
Volume	28
Issue number	30
DOIs	https://doi.org/10.1200/JCO.2009.27.1932
Publication status	Published - 20 Oct 2010

Access to Document

10.1200/JCO.2009.27.1932

http://jco.ascopubs.org/content/28/30/4601

Cite this

@article{f47da51917ba4d0fb12b0f765f114e9c,

title = "Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma",

abstract = "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG.",

author = "Michael Brada and Sally Stenning and Rhian Gabe and Thompson, {Lindsay C} and David Levy and Roy Rampling and Sara Erridge and Frank Saran and Rao Gattamaneni and Kirsten Hopkins and Sarah Beall and Collins, {V Peter} and Siow-Ming Lee",

year = "2010",

month = oct,

day = "20",

doi = "10.1200/JCO.2009.27.1932",

language = "English",

volume = "28",

pages = "4601--1408",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "30",

}

TY - JOUR

T1 - Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma

AU - Brada, Michael

AU - Stenning, Sally

AU - Gabe, Rhian

AU - Thompson, Lindsay C

AU - Levy, David

AU - Rampling, Roy

AU - Erridge, Sara

AU - Saran, Frank

AU - Gattamaneni, Rao

AU - Hopkins, Kirsten

AU - Beall, Sarah

AU - Collins, V Peter

AU - Lee, Siow-Ming

PY - 2010/10/20

Y1 - 2010/10/20

N2 - Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG.

AB - Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG.

UR - http://www.scopus.com/inward/record.url?scp=78049515473&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.27.1932

DO - 10.1200/JCO.2009.27.1932

M3 - Article

C2 - 20855843

SN - 0732-183X

VL - 28

SP - 4601

EP - 1408

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 30

ER -

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma

Abstract

Access to Document

Other files and links

Cite this